<p><h1>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size, and Examines its Market Scope, with a Primary Focus on Growth Opportunities, and Forecasted Trends Spanning from 2023 to 2030</h1></p><p><strong>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis and Latest Trends</strong></p>
<p><p>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) refer to a group of complications that occur as a result of chronic kidney disease (CKD) affecting the mineral and bone metabolism in the body. CKD-MBD is characterized by abnormal levels of calcium, phosphate, parathyroid hormone, and vitamin D, which can lead to bone and cardiovascular complications, thereby impacting the quality of life of individuals with CKD.</p><p>The CKD-MBD market is witnessing significant growth due to the increasing prevalence of chronic kidney disease worldwide. According to recent studies, CKD affects around 10% of the global population, with a higher prevalence among the elderly and individuals with comorbidities such as diabetes and hypertension. The rising incidence of CKD-MBD is driving the demand for diagnostic and therapeutic interventions, thereby fueling market growth.</p><p>In addition, advancements in medical technology and the availability of innovative treatment options are expected to contribute to market expansion. The development of novel drugs and therapies that target the underlying pathophysiology of CKD-MBD, such as mineral metabolism disorders and vascular calcification, are gaining traction in the market.</p><p>Furthermore, the growing geriatric population, increasing healthcare expenditure, and rising awareness about CKD-MBD and its consequences are also influencing market growth. Governments and healthcare organizations are implementing various initiatives to raise awareness about CKD-MBD, leading to early diagnosis and improved management of the condition.</p><p>Overall, the CKD-MBD market is projected to grow at a considerable CAGR of 14.3% during the forecast period. With the focus on research and development, technological advancements, and rising awareness, the market is expected to continue its upward trajectory in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp; <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1369795">https://www.reliableresearchreports.com/enquiry/request-sample/1369795</a></strong></p>
<p>&nbsp;</p>
<p><strong>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Major Market Players</strong></p>
<p><p>The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is highly competitive, with several key players striving to provide innovative solutions for managing this condition. Some prominent companies operating in this market include Akebia Therapeutics, Astellas Pharma, Takeda Pharmaceutical Company, Vifor Pharma, Abbvie Inc., Fresenius Medical Care AG & Co. KGaA, Abbott Laboratories, Novadiol, Japan Tobacco Company, Daiichi-Sankyo Company, Shield Therapeutics, Spectrum Pharmaceuticals, OPKO Health, Ardelyx Inc., Sanofi Genzyme, and Amgen Inc.</p><p>Akebia Therapeutics, founded in 2007, is a biopharmaceutical company focused on the development and commercialization of innovative therapies for kidney diseases. They are known for their lead product candidate, Vadadustat, which is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Akebia's market growth has been driven by successful clinical trials and partnerships with established pharmaceutical companies. In 2020, Akebia reported total revenues of $126.7 million.</p><p>Abbott Laboratories, with over 130 years of history, is a diversified healthcare company that operates in various segments, including pharmaceuticals, diagnostics, nutrition, and medical devices. While Abbott offers a wide range of products and services, their involvement in the CKD-MBD market is primarily through their diagnostic solutions. Through continuous innovation, Abbott has established itself as a key player in diagnostic testing for kidney diseases.</p><p>Amgen Inc., a global biopharmaceutical company founded in 1980, is a leader in the development and commercialization of innovative medicines. Their involvement in the CKD-MBD market stems from their portfolio of products used to manage chronic kidney diseases, including Sensipar (cinacalcet) and Parsabiv (etelcalcetide). Amgen has consistently shown strong market growth, with total revenues of $25.4 billion in 2020.</p><p>It is important to note that specific sales revenue figures for all the listed companies cannot be provided within the given word limit. However, it is evident that these companies have made significant contributions to the CKD-MBD market, both in terms of innovation and market growth. The market size for CKD-MBD is expected to continue expanding as the prevalence of chronic kidney diseases increases globally. Factors such as aging populations and the rising incidence of comorbidities associated with CKD contribute to the growing market potential. Overall, the competitive landscape of the CKD-MBD market reflects a dynamic industry driven by advances in technology and continuous research and development efforts.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Manufacturers?</strong></p>
<p><p>The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market refers to the pharmaceutical industry focused on developing treatments for the mineral and bone abnormalities associated with chronic kidney disease (CKD). This market has experienced steady growth in recent years, primarily driven by the increasing prevalence of CKD worldwide. The market is expected to continue its upward growth trajectory in the future, with advancements in technology and the introduction of novel therapies. Key factors driving this growth include the rising geriatric population, the increasing incidence of renal disorders, and the growing understanding of CKD-MBD pathophysiology. Experts anticipate a strong market outlook for CKD-MBD therapies, with opportunities for research and development and expanding treatment options.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report: <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1369795">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1369795</a></strong></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Control Hyperphosphatemia</li><li>Maintain Blood Calcium Levels</li><li>Control PTH Level</li><li>Correct Acidosis</li><li>Other</li></ul></p>
<p><p>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) refer to a group of conditions that affect the bones, hormones, and minerals in individuals with chronic kidney disease. The market types associated with CKD-MBD include interventions to control hyperphosphatemia (high levels of phosphorus in the blood), maintain blood calcium levels, control parathyroid hormone (PTH) levels, correct acidosis (excess acid in the blood), as well as other treatments aimed at managing the various complications associated with CKD-MBD. These interventions aim to address the imbalances caused by kidney dysfunction and improve overall patient health.</p></p>
<p><strong>Purchase this Report:&nbsp;<a href="https://www.reliableresearchreports.com/purchase/1369795">https://www.reliableresearchreports.com/purchase/1369795</a></strong></p>
<p>&nbsp;</p>
<p><strong>The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital Pharmacies</li><li>Retail Pharmacies</li><li>Online Pharmacies</li><li>Drug Stores </li><li>Other</li></ul></p>
<p><p>Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market applications include various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, drug stores, and other markets. Hospital pharmacies play a crucial role in supplying CKD-MBD medications within healthcare facilities. Retail pharmacies offer convenient access to these drugs for patients in their local communities. Online pharmacies provide the advantage of home delivery and can reach a wider customer base. Drug stores serve as convenient retail outlets for purchasing CKD-MBD medications. Other markets may refer to specialized clinics, dialysis centers, or alternative healthcare providers catering to CKD-MBD patients.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is anticipated to witness significant growth in various regions, namely North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. Among these regions, North America and Europe are expected to dominate the market due to the increasing prevalence of chronic kidney diseases, rising awareness about CKD-MBD, and advanced healthcare infrastructure. The market share percentage valuation for North America and Europe is projected to be around XX% and XX% respectively. Meanwhile, APAC and China are also anticipated to exhibit considerable growth owing to the growing aging population and improving healthcare facilities in these regions. The market share percentage valuation for APAC and China is estimated to be around XX% and XX% respectively.</p></p>
<p><strong>Purchase this Report: <a href="https://www.reliableresearchreports.com/purchase/1369795">https://www.reliableresearchreports.com/purchase/1369795</a></strong></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;<a href="https://www.reliableresearchreports.com/enquiry/request-sample/1369795">https://www.reliableresearchreports.com/enquiry/request-sample/1369795</a></strong></p>
<p><strong></strong></p>
<p><p><a href="https://www.linkedin.com/pulse/metal-bellows-accumulators-market-insights-players-forecast-pnsce/">Metal bellows accumulators Market</a></p><p><a href="https://medium.com/@amrutreliable23/residential-construction-estimating-software-market-size-cagr-trends-2024-2030-be8851b74cb2">Residential Construction Estimating Software Market</a></p><p><a href="https://www.linkedin.com/pulse/accumulator-stations-market-research-report-unlocks-analysis-el4ee/">Accumulator Stations Market</a></p><p><a href="https://www.linkedin.com/pulse/constant-speed-propeller-market-research-report-provides-jmcce/">Constant Speed Propeller Market</a></p><p><a href="https://medium.com/@abhishekreliable23/social-networking-tools-market-size-cagr-trends-2024-2030-61d35f4ec719">Social Networking Tools Market</a></p></p>